Skip to main
CLSD
CLSD logo

Clearside Biomedical (CLSD) Stock Forecast & Price Target

Clearside Biomedical (CLSD) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Clearside Biomedical Inc. has achieved promising results with its CLS-AX candidate in recent clinical trials, indicating potential advancements in the treatment of wet age-related macular degeneration (wAMD) with a more flexible dosing regimen compared to existing therapies. The company's proprietary SCS Microinjector platform not only enhances patient experience with fewer injections but also opens avenues for additional revenue through collaborations with partners developing their own drug candidates for administration via the suprachoroidal space. Continued success in clinical trials and strategic partnerships could significantly drive Clearside's growth in revenue and market position within the ophthalmic therapeutic landscape.

Bears say

Clearside Biomedical faces significant risks related to the efficacy and safety of its retinal disease treatment candidate, CLS-AX, which could lead to substantial setbacks in its clinical development. Key uncertainties include the potential failure of CLS-AX in clinical trials, its ability to secure necessary regulatory approvals, and challenges in achieving commercial success amid competition and market limitations. Additionally, the company is exposed to dilution risks, further compounding concerns about its financial stability and growth prospects.

Clearside Biomedical (CLSD) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearside Biomedical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearside Biomedical (CLSD) Forecast

Analysts have given Clearside Biomedical (CLSD) a Buy based on their latest research and market trends.

According to 12 analysts, Clearside Biomedical (CLSD) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearside Biomedical (CLSD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.